To the full analysis
Omega Healthcare Investors stock: growth
OHIOmega Healthcare Investors reported $1.2B in revenue for fiscal 2025, up 14% on the prior year, up 6.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
12.2%
per year from 2006 to 2025, per share 3%
Earnings (Annual rate)
13.2%
per year from 2006 to 2025, per share 5.1%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.1% | 4.9% | 12.2% |
| Revenue per share | 0.6% | −0.6% | 3.0% |
| Earnings | 29.9% | 10.1% | 13.2% |
| Earnings per share | 23.6% | 4.5% | 5.1% |
| Free cash flow | 6.8% | 11.4% | no data |
| Free cash flow per share | 1.3% | 5.5% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $135.51M | $55.7M | −$122.9M |
| 2007 | $159.56M | $69.37M | $36.49M |
| 2008 | $193.76M | $78.14M | −$40.89M |
| 2009 | $197.44M | $82.11M | −$35.49M |
| 2010 | $258.32M | $58.44M | −$221.64M |
| 2011 | $292.2M | $52.61M | $63.47M |
| 2012 | $350.46M | $120.7M | $208.27M |
| 2013 | $418.71M | $172.52M | $279.95M |
| 2014 | $504.79M | $221.35M | $337.54M |
| 2015 | $743.62M | $224.52M | $299.66M |
| 2016 | $900.83M | $366.42M | $556.81M |
| 2017 | $908.39M | $100.42M | $491.22M |
| 2018 | $881.68M | $281.58M | $359.93M |
| 2019 | $928.83M | $341.12M | $414.07M |
| 2020 | $892.38M | $159.33M | $633.15M |
| 2021 | $1.06B | $416.74M | $627.07M |
| 2022 | $878.24M | $426.93M | $578.51M |
| 2023 | $949.74M | $242.18M | $588.53M |
| 2024 | $1.05B | $406.33M | $711.67M |
| 2025 | $1.2B | $590.11M | $878.55M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.